Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy

Annals of Oncology

Volumn 15, Issue 11, 2004, Pages 1661-1666

  Yeo, Winnie ^a   Lam, K C ^a   Zee, B ^a   Chan, P S K ^a   Mo, F K F ^a   Ho, W M ^a   Wong, W L ^a   Leung, T W T ^a   Chan, A T C ^a   Ma, B ^a   Mok, T S K ^a   Johnson, P J ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chemotherapy; HBsAg; Liver cancer; Viral reactivation

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CISPLATIN; CORTICOSTEROID; DOXORUBICIN; FAMCICLOVIR; FLUOROURACIL; GANCICLOVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; INOPERABLE CANCER; LIVER CELL CARCINOMA; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; VIRUS REACTIVATION;

ADULT; AGED; ALANINE TRANSAMINASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DNA, VIRAL; DOXORUBICIN; FEMALE; FLUOROURACIL; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOENZYME TECHNIQUES; INTERFERON ALFA-2B; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 9444277289     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh430     Document Type: Article

References (28)

1. Hong Kong Hospital Authority. Cancer incidence and mortality in Hong Kong 1993-1994. Hong Kong Cancer Registry 1998.
2. Okuda K, Ohtsuki T, Obata H et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer (Phila.) 1985; 56: 918-928.
3. Simonetti RG, Leberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials. Ann Oncol 1997; 8: 117-136.
4. Johnson PJ. Hepatocellular carcinoma: is current therapy really altering outcome? Gut 2002; 51: 459-462.
5. Ho J, Wu PC, Kung TM. An autopsy study of hepatocellular carcinoma in Hong Kong. Pathology 1981; 13: 409-416.
6. Lok ASF, Lai CL, Wu PC et al. Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol 1987; 126: 492-499.
7. Galbraith RM, Eddleston AL, Williams R, Zuckerman Al. Fulminating hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975; 2: 528-530.
8. Nakamura Y, Motokura T, Fujita A et al. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies-Survey in Japan, 1987-1991. Cancer 1996; 78: 2210-2215.
9. Kumagai K, Takagi T, Nakamura S et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997; 8: 107-109.
10. Lok ASF, Liang RHS, Chiu EKW et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Gastroenterology 1991; 100: 182-188.
11. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer 1999; 81: 69-74.
12. Yeo W, Chan PKS, Zhong S et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307.
13. Liang RHS, Lok ASF, Lai CL et al. Hepatitis B infection in patients with lymphomas. Hemat Oncol 1990; 8: 261-270.
14. Yeo W, Zee B, Zhong S et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-1311.
15. Nerenstone SR, Ihde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev 1988; 15: 1-31.
16. Leung TWT, Patt YZ, Lau WY et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999; 5: 1676-1681.
17. Yeo W, Zhong S, Chan PKS et al. Sequence variations of precore/core and precore promoter regions of hepatitis B virus in patients with or without viral reactivation during cytotoxic chemotherapy. J Viral Hep 2000; 7: 448-458.
18. Nagamatsu H, Kumashiro R, Itano S et al. Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC. Hepatol Res 2003; 26: 293-301.
19. Hoofnagle JH, Dusheiko GM, Schafer DF et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982; 96: 447-449.
20. Ohtsu T, Sai T, Oka M et al. Activation of Hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematologic malignancies. Jpn J Clin Oncol 1991; 21: 360-365.
21. Chou CK, Wang LH, Lin HM, Chi CW. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. Hepatology 1992; 16: 13-18.
22. Yeo W, Chan PKS, Chan HLY et al. Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. J Med Virol 2001; 65: 473-477.
23. Pramoolsinsup, C. Management of viral hepatitis B (Quadrennial Review). J Gastroenterol Hepatol 2002; 17 (Suppl): S125-S145.
24. Di Bisceglie AM, Fong TL, Fried MW et al. A randomized, controlled trial of recombinant interferon-alpha therapy for chronic hepatitis B. Am J Gastroenterol 1993; 88: 1887-1892.
25. Lok ASF, Chung HT, Liu VWS, Ma OC. Long-term follow-up of chronic hepatitis B patients treated with interferon-alpha. Gastroenterology 1993; 105: 1833-1838.
26. Yuen MF, Hui CK, Cheng CC et al. Long-term follow-up of interferon-alpha treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e Antigen seroconversion and development of cirrhosis-related complications. Hepatology 2001; 34: 139-145.
27. Yeo W, Chan PKS, Ho WM et al. Lamivudine for the prevention of hepatitis B virus reactivation in HBsAg seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 90: 1306-1311.
28. Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001; 115: 58-62.